Industries > Pharma > Rheumatoid Arthritis (RA): World Drug Market 2013-2023

Rheumatoid Arthritis (RA): World Drug Market 2013-2023

PUBLISHED: 19 April 2013
PAGES: 120

WOOCS 2.2.1
SKU: N/A Categories: , , ,

Now discover trends, opportunities and revenue prospects for treating rheumatoid arthritis

Where’s the arthritic treatment market heading? Visiongain’s updated report gives you forecasted revenues to 2023 for drugs treating human rheumatoid arthritis (RA). There you find R&D trends, outlooks and commercial opportunities.

Our study lets you assess sales data and predictions for the world RA medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field’s most promising and lucrative segments.

Established and emerging anti-rheumatic technologies have potential. Read on to scan features of that industry, find what drives it, and see what its future market could be worth.

Forecasts and other analyses to help you understand the RA market

Our report gives you revenue forecasts to 2023, historical data, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and developments (R&D). You also gain 56 tables, 47 charts and three research interviews.

With our study you can stay ahead in knowledge, benefiting your research, analyses and decisions. There you find trends, innovations and opportunities for treating rheumatoid arthritis. You see what’s happening, discovering possibilities.

There’s rising need worldwide for drugs to treat arthritis. For RA medicines, our work helps you find business areas that can prosper most, reducing the risk of your missing out.

The following sections, then, show how you benefit from our new study.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market for treating RA, our work shows forecasts to 2023 for submarkets:
• Biologics (biological drugs, e.g. monoclonal antibodies [mAbs])
• Non-biologics (other therapeutic molecules).

For the non-biologics submarket, you get further revenue breakdowns to 2023:
• Conventional DMARDs
• Others agents (grouped, including novel DMARDs and corticosteroids).

From 2013, how will the RA drugs market grow? Which areas will most prosper? For anti-rheumatic medicines, our report helps you identify growth potential and find opportunities.

See prospects for manufacturers of novel drugs, generics and biosimilars, including follow-on and next-generation products.

Also our investigation discusses what stimulates and restrains business. There you explore dynamics of that industry, also seeing what products can achieve the most success.

See revenue forecasts for leading drugs

How will leading anti-arthritic agents perform to 2023 at world level? Our study forecasts sales of 10 leading RA products and one emerging drug:
• Celebrex
• Arcoxia
• Remicade
• Humira
• Enbrel
• Orencia
• Simponi
• Actemra
• Cimzia
• Xeljanz.

There you discover how high sales can go, to 2023, finding drugs and years with highest predicted revenues and growth. Also, you see how competitors compare – assess competition. You find what’s happening, understanding trends, challenges and opportunities.

Our analysis also divides its overall world RA revenue forecast into those for main geographical markets.

What prospects for leading regions and countries?

In developed and developing countries – especially India and China – there remain many opportunities for selling drugs to treat rheumatoid arthritis. There you see opportunities for developers, producers and sellers of those medicines.

Our study shows you individual revenue forecasts to 2023 for eleven national markets:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).

There you discover progress and outlooks. That way, you assess the industry’s future – hear about developments and find their significance.

Our forecasting shows revenue growth will occur in established pharma markets and in developing countries. In particular, product launches from 2013 to 2023 will change anti-rheumatic drug prescribing and the commercial landscape. See how.

Research and development – assess innovation, trends and possibilities

What about R&D – the pipeline for new RA drugs? You see developmental trends for these agents and others:
• Biologics, including biosimilars
• Corticosteroids
• Other agents (e.g. JAK inhibitors).

In our work you assess innovations, hearing about developments and finding their significance. Discover progress.

See, then, what the future holds. For large companies and specialty pharma firms there exist many opportunities in treating rheumatoid arthritis. Our study explains, discussing many issues.

What affects the anti-arthritics drug sector?

Our report discusses issues and events affecting that industry and market from 2013, including these developments:
• Current and future use of treatments
• Unmet and under-met needs for treating rheumatoid arthritis
• Janus kinase inhibitors and anti-TNF therapy
• Adverse effect profiles and patient compliance
• Regulatory challenges and developments
• Novel small-molecule therapies
• Demand for more-efficacious and better-tolerated drugs
• Biosimilars – a threat to original novel products?

That way, you explore technological, economic, social and political (STEP) questions, assessing outlooks for that area of business.

Our investigation also lets you analyse the RA treatment industry’s strengths, weaknesses, opportunities and threats (SWOT). See, then, what the future holds.

Leading companies and 2017 market value

What happens next? Our study predicts the overall world market for anti-arthritic drugs will reach $38.5bn in 2017. There, you also see how that market performs to 2023.

Our analyses show you what products and organisations there hold greatest potential. That work explores these leading five companies and others:
• Abbott Laboratories (AbbVie)
• Roche
• Pfizer
• Johnson & Johnson
• Amgen.

Also, you read three interviews with authorities on that field. See what shapes it, discovering what participants think, feel, do and say.

Prospects for R&D on arthritis are encouraging, and from 2013 onwards there will arise many opportunities. Our work shows you technological, medical and commercial possibilities, helping you stay ahead.

Ten ways Rheumatoid Arthritis (RA): World Drug Market 2013-2023 helps you

In particular then, our investigation gives you the following knowledge:
• Revenues to 2023 for the world RA drugs market – discover that industry’s overall sales prospects
• Revenues to 2023 for 5 world-level submarkets – investigate the potential of that industry’s components, finding the most-promising areas for investments and revenues
• Revenues to 2023 for 11 products – find sales outlooks for top brands, seeing how they can compete and succeed
• Forecasts to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China – see national sales potentials, finding the best regions for revenues and growth
• Review of R&D for treating rheumatoid arthritis – investigate progress in its research areas, finding technological and medical possibilities
• Discussions of leading companies, including profiles of the top 5 players – hear about strategies, capabilities, results and outlooks
• Interviews with authorities in that field – discover debates and opinions to help you stay ahead
• Competition and opportunities – see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business
• Analysis of what stimulates and restrains the industry and market – assess challenges and strengths, helping you compete and gain advantages
• Prospects for established competitors and firms seeking to enter the sector -explore needs, practices and outlooks for future success.

You gain information found nowhere else

That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.

Ordering now lets you discover predictions to 2023 for RA medical trends and revenues

Our investigation is for everyone needing analysis of the industry and market for anti-rheumatic medicines. There you find data, trends, opportunities and predictions. Please order that report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for Rheumatoid Arthritis (RA): World Drug Market 2013-2023

Download sample pages

Complete the form below to download your free sample pages for Rheumatoid Arthritis (RA): World Drug Market 2013-2023

Latest Pharma news

Visiongain Publishes Single-Cell Analysis Market Report 2022-2032

The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

26 May 2022


Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022


Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022


Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022